miRNA-based Regenerative Therapy

About Heqet Therapeutics

Heqet Therapeutics is an early-stage Italian biotech pioneering a novel approach to cardiac regeneration following myocardial infarction (MI). Its core technology involves the upregulation of specific non-coding RNAs, primarily microRNAs (miRNAs), to stimulate cardiomyocyte proliferation and repair damaged heart tissue, targeting pathways like Hippo and actin cytoskeleton regulation. Founded on strong academic research with multiple key publications, including promising large animal (pig) data, the company is positioned to tackle the significant unmet need of preventing heart failure post-MI. As a private, pre-clinical, and pre-revenue entity, its near-term focus is advancing its lead programs through development.

Therapeutic Areas